Conditions · Pancreatic cancer
Pancreatic cancer — Phase 1 trials
Prefer to look first? Browse the live map without signing up.
28 open options
- TRIALPHASE1NOT_YET_RECRUITING
Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer
NP137 — 1 site
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC
SHR-1701 · Apatinib · gemcitabine — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
AGEN2373 · Balstilimab · Cyclophosphamide — 1 site
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer
Samuraciclib + Gemcitabine & Nab-Paclitaxel — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
JAB-23E73 · JAB-23E73 — 32 sites
- TRIALPHASE1 / PHASE2RECRUITING
Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer
EGFR FPBMC — 1 site
- TRIALPHASE1RECRUITING
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
ASP2138 · Pembrolizumab · Oxaliplatin — 46 sites
- TRIALPHASE1 / PHASE2RECRUITING
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VMD-928 100 mg Tablet · VMD-928 Tablet and Pembrolizumab (200 mg) — 15 sites
- TRIALPHASE1RECRUITING
A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
ELI-002 7P · Tislelizumab · mFOLFIRINOX — 7 sites
- TRIALPHASE1RECRUITING
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
KST-6051 — 9 sites
- TRIALPHASE1RECRUITING
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
CEA-targeted CAR-T cells — 2 sites
- TRIALPHASE1NOT_YET_RECRUITING
64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer
Biospecimen Collection · Copper Cu 64-DOTA-A2DM · Positron Emission Tomography — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
EBNK-001 + IL-15 + Pembrolizumab — 1 site
- TRIALPHASE1NOT_YET_RECRUITING
Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC
Oncolytic virus Plus Anti-PD1 and Chemotherapy — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
CT3001 · FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) — 1 site
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer
Oncolytic virus VRT106 · Chemotherapy — 1 site
- TRIALPHASE1RECRUITING
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
Fulvestrant · 177Lu-DOTATATE — 1 site
- TRIALPHASE1RECRUITING
A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma
DA-3501 — 3 sites
- TRIALPHASE1RECRUITING
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Sofe-M · bevacizumab · carboplatin — 24 sites
- TRIALPHASE1NOT_YET_RECRUITING
A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)
CLSP-5282 — 4 sites
- TRIALPHASE1RECRUITING
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
INCB161734 · Cetuximab · Retifanlimab — 34 sites
- TRIALPHASE1RECRUITING
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
LY4052031 — 39 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
BMS-986523 · Gemcitabine · Nab-Paclitaxel — 8 sites
- TRIALPHASE1 / PHASE2RECRUITING
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
XNW28012 — 24 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
A2B694 · A2B543 · xT CDx with HLA-LOH Assay — 12 sites
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study)
Radiotherapy · Immunotherapy:Granulocyte macrophage-colony stimulating factor(GM-CSF)、Cadumilimab · Chemotherapy:Albumin-bound paclitaxel、Gemcitabine
- TRIALPHASE1RECRUITING
The Purpose of This Study is to Evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Monotherapy in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC)
TMT101 Injection — 1 site
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.